BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Poised to Successfully Commercialize Its Products

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. At the moment, Odyssey’s market profile includes two medical device candidates and two pharmaceutical products in development. The portfolio is responding to varied needs, including patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing with a rare neurodegenerative disorder, and patients needing treatment for brain concussion injuries,” a recent article reads. “CEO Michael Redmond spoke with The RedChip Money Report(R) on Bloomberg TV to explain the company’s model… ‘They have strong IP positions – on all three of them,’ Redmond said [of the company’s drug-device combination for treating concussion, a cardiological prototype device, and an anti-choking device]. ‘We believe that we have the management, the board of directors, and the experience level … that will allow us to successfully commercialize all three of these products and create significant value for the company.’”

To view the full article, visit https://ibn.fm/oTaTy

About Odyssey Health Inc. (formerly Odyssey Group International Inc.)

Odyssey is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…

24 hours ago

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million

Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, up…

24 hours ago

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…

4 days ago

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ:…

4 days ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers…

4 days ago

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year…

4 days ago